Morphine pharmacokinetics were studied in 17 premature neonates (26-34 weeks' gestation) after intravenous infusion during the first 24 hours of life. Infants received either standard dose morphine that comprised ofa 100 jig/kg/hour loading infusion for 2 hours followed by a maintenance infusion of 12-5 jig/kg/hour, or a high dose of 200 jig/kg/hour for 2 hours followed by 50 jig/kg/hour. Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12-9) and 96-4 (3-2) ng/ml, and 184-2 (37-7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively. Morphine-3-glucuronide plasma concentrations achieved about 20% and 8O0/o of morphine values at 2 and 24 hours respectively. Morphine-6-glucuronide could not be detected at 2 hours, but attained 20-25% of morphine plasma concentrations by 24 hours. The population mean morphine clearance was 2-4 ml/min/kg, the elimination half life was 8-75 hours and the volume of distribution was 1-82 I/kg. High plasma concentrations of morphine appeared to be well tolerated. Although mean arterial blood pressure decreased during the first six hours of treatment, this was not statistically significant; two infants experienced transient muscle rigidity, but no evidence of seizures was noted. There appears to be no clinical advantage in using the high dose regimen.
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where n is expressed in multiples of the tl/, of the drug (that is n is the time t divided by t'/2). Trends suggesting an increase in the clearance of morphine with increasing birth weight and gestational age were observed, but these did not achieve significance (r=0-310 and 0-630, respectively; nine data pairs, p>005). The population mean clearance of morphine was 2-4 ml/min/kg (n=9). The population mean 38-3(4-4)
9-0 ty/2 for morphine was found to be 8&75 hours. This value provided the 'best fit' when mean (SE) measured plasma concentrations of morphine were superimposed on simulated plasma concentration-time profiles (using tb/2 values from 8-9 hours) for the standard and high dose regimens ( figure) . The population mean volume of distribution derived from these two pharmacokinetic parameters was 1 82 V/kg.
CLINICAL OBSERVATIONS
Mean arterial blood pressure data from seven infants receiving the high dose regimen are presented in table 2. Although mean blood pressure decreased between 6A4-107% during the first 6 hours of morphine infusion, these changes were not statistically significant (p>0 05); the largest decrease noted after 2 hours coincided with the completion of the loading infusion. Despite careful observation, there was no indication of seizures during the first 24 hours, but we did note transient hypertonia in two infants.
Discussion
The need for multiple samples in pharmacokinetic studies involving premature neonates can present a problem. Clearly, the volume of blood that can justifiably be obtained from acutely ill preterm infants is limited, particularly in the first 24 hours of treatment. The approach outlined in this study, using simulation techniques, provides a way of obtaining population estimates of pharmacokinetic parameters and minimises the sample requirement to only four samples per infant. The population mean morphine plasma clearance of 2-4 ml/min/kg is slightly lower than previously published values of 4 7, 3 39, and 3-6 ml/min/kg in preterm infants,9 1112 but this may be due to differences in postnatal age between the present (<1 day) and earlier study populations (>2 days). The relatively high morphine plasma concentrations resulting from the high dose regimen (182-4 and 319 ng/ml at 2 and 24 hours, respectively) were well tolerated. Mean blood pressure decreased during the first six hours, the maximum change (10-7%) was noted at 2 hours corresponding with completion of the loading infusion. However, the changes in mean blood pressure were not statistically significant and were not associated with clinical deterioration. Indeed, although we have data from only seven infants, these changes may reflect a transition from higher blood pressure values in stressed babies to more normal values as the sedative and analgesic effects of morphine settle the infants. Giving the loading dose over 2 hours appears to alleviate concern regarding reductions in blood pressure when opioid drugs are given as an intravenous bolus.19 Despite careful clinical observation, we found no evidence to support the view that high plasma morphine concentrations are associated with seizures. 20 We did note transient hypertonia in two infants but this did not necessitate termination of the morphine infusion. As clinical effect seems to be unaffected by dosage increment, there appears to be no advantage in using the high dose regimen.
